Anthera Pharmaceuticals, Inc. (ANTH Quick QuoteANTH - Free Report) was a big mover last session, as its shares rose almost 8% on the day. The move came after the company announced an independent expert advisory group gave a positive review of a late-stage clinical trial of its cystic fibrosis drug. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.01 to $3.29 in the past one-month time frame..

None of the estimates for this stock were revised over the past 30 days while the Zacks Consensus Estimate moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent move higher can last.

Anthera Pharmaceuticals currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is positive.

ANTHERA PHARMA Price

ANTHERA PHARMA Price | ANTHERA PHARMA Quote

A better-ranked stock in the med-biomed/gene space is Geron Corporation (GERN Quick QuoteGERN - Free Report) , which sports a Zacks Rank #1 (Strong Buy).

Is ANTH going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>